SAPIEN 3瓣膜TAVR术后瓣周反流与1年结局的关联
该研究基于PARTNER II SAPIEN 3试验的多中心非随机注册数据,纳入1661例中高危主动脉瓣狭窄患者,经导管主动脉瓣置换术后用核心实验室评估瓣周反流。结果显示30天时至少中度瓣周反流仅占3.5%,但与1年死亡和心衰再住院风险升高相关;轻度至中度反流无显著影响。多数30天至少中度反流患者1年内反流程度减轻。
要点
- SAPIEN 3术后30天至少中度瓣周反流发生率低(3.5%)。
- 至少中度瓣周反流与1年死亡及心衰再住院风险升高独立相关。
- 轻度至中度(5分类法)瓣周反流对短期死亡或再住院无显著影响。
核心结论
- SAPIEN 3瓣膜TAVR术后至少中度瓣周反流虽少见,但与1年死亡和心衰再住院风险增加相关。
- 轻度至中度瓣周反流(5分类法)对短期死亡或再住院无显著影响。
- 多数30天至少中度瓣周反流患者1年内反流严重程度至少改善1个等级。
研究设计与样本
- PARTNER II SAPIEN 3试验的预设分析,为多中心非随机注册研究。
- 纳入1661例中高危重度症状性主动脉瓣狭窄患者,来自美国和加拿大51个中心。
- 其中1592例接受SAPIEN 3瓣膜并完成瓣周反流评估。
- 瓣周反流由核心实验室在30天和1年按5分类法评估。
主要发现
- 30天时55.7%患者无或微量瓣周反流,32.6%为轻度,8.2%为轻度至中度,3.5%至少中度。
- 1年时9.3%患者死亡,14.2%患者再住院。
- 1213例配对比较中,73%的30天至少中度瓣周反流患者1年时反流严重程度至少改善1个等级。
关键数值与推荐
- 瓣周反流采用5分类法:0无或微量,1轻度,2轻度至中度,3中度,4中度至重度,5重度。
临床怎么用
- TAVR术后应关注至少中度瓣周反流,因其与1年不良结局相关。
- 轻度至中度瓣周反流(5分类法)短期风险未见显著增加,可密切随访。
- 多数至少中度瓣周反流可随时间改善,但需监测高危患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Moderate/severe and even mild paravalvular regurgitation (PVR) are associated with increased mortality following transcatheter aortic valve replacement (TAVR) with first and second generations of transcatheter valves. OBJECTIVE: To examine the incidence, evolution, and effect on 1-year outcomes of PVR following TAVR with a third-generation balloon-expandable transcatheter heart valve. DESIGN, SETTING, AND PARTICIPANTS: Prespecified analysis of PVR in the Placement of Aortic Transcatheter Valves (PARTNER) II SAPIEN 3 trial, conducted between October 1, 2013, and September 3, 2014. Multicenter, nonrandomized registry of 1661 patients at intermediate or high surgical risk undergoing TAVR with the SAPIEN 3. Patients with severe, symptomatic aortic stenosis and high/intermediate surgical risk were enrolled in the registry at 51 sites in the United States and Canada. INTERVENTIONS: Transcatheter aortic valve replacement with the SAPIEN 3 valve. MAIN OUTCOMES AND MEASURES: Paravalvular regurgitation was assessed in a core laboratory at 30 days and 1 year according to a 5-class scheme: 0, none or trace; 1, mild; 2, mild to moderate; 3, moderate; 4, moderate to severe; and 5, severe. We assessed the effect of PVR on 1-year mortality and heart failure rehospitalization. RESULTS: Among the 1661 included in the registry, 1592 received a SAPIEN 3 valve and had assessment of PVR. Of these patients, 55.7% had none-trace PVR, 32.6% had mild, 8.2% had mild to moderate, and 3.5% had at least moderate PVR at 30 days. At 1 year, 9.3% of patients had died and 14.2% had been rehospitalized. Only patients with at least moderate PVR had higher 1-year mortality (hazard ratio [HR], 2.40; 95% CI, 1.30-4.43; P = .005) and composite of mortality/rehospitalization (HR, 2.35; 95% CI, 1.52-3.62; P < .001). In a paired comparison including 1213 patients, 73% of the patients with at least moderate PVR at 30 days showed a reduction in PVR severity of at least 1 PVR class at 1 year. CONCLUSIONS AND RELEVANCE: In this series of patients undergoing TAVR with the SAPIEN 3 valve, at least moderate PVR was rare but associated with increased risk of death and heart failure rehospitalization at 1 year. Even the upper range of the mild class in the 3-class grading scheme (ie, mild to moderate in the 5-class scheme) had no significant effect on short-term mortality or rehospitalization. Most patients with at least moderate PVR at 30 days showed a decrease of PVR severity grade at 1 year. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01314313.
引用
- Pibarot P, Hahn RT, Weissman NJ, et al. Association of Paravalvular Regurgitation With 1-Year Outcomes After Transcatheter Aortic Valve Replacement With the SAPIEN 3 Valve. JAMA Cardiol. 2017. PMID: 28973091. doi:10.1001/jamacardio.2017.3425
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。